This technology is a biodosimeter capable of rapidly detecting and assessing the degree of radiation exposure using human blood samples that can be used at the point of care.
Following a large-scale radiological or nuclear event, large numbers of people may be exposed to ionizing radiation and require rapid and dose-dependent medical treatment. Current biodosimetry methods are time-intensive and difficult to scale up to meet the demands of such events. Therefore, there is a need for a more effective tool capable of identifying and measuring human exposure to ionizing radiation that can scale up to quickly assess larger sample sizes.
This technology is an ELISA-based immunoassay platform that rapidly detects and quantifies a panel of radio-responsive protein biomarkers in blood lymphocytes that can be found in the blood of individuals recently exposed to ionizing radiation. The presence of these proteins can be used to accurately predict the degree of radiation exposure up to one week post-exposure. A custom machine learning module integrates measurements from multiple biomarkers, including intracellular proteins (BAX, DDB2) and plasma proteins, along with cell counts and viability data, to classify radiation exposure and predict absorbed dose. The system categorizes exposure into clinically relevant dose ranges that correspond to specific treatment decisions, enabling medical providers to rapidly triage patients and initiate appropriate interventions. The technology is capable of testing 40 samples in ~4 hours or 400 samples in ~15 hours, ensuring same-day diagnosis and thereby allowing medical providers to more quickly address the exposure and begin treatment.
This technology has been validated in ex vivo human blood models and non-human primate models.
Patent Pending (WO/2025/217542)
IR CU24211
Licensing Contact: Joan Martinez